Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nosocomial bloodstream infections (BSIs) are important causes of morbidity and mortality in the United States. METHODS: Data from a nationwide, concurrent surveillance study (Surveillance and Control of Pathogens of Epidemiological Importance [SCOPE]) were used to examine the secular trends in the epidemiology and microbiology of nosocomial BSIs. RESULTS: Our study detected 24,179 cases of nosocomial BSI in 49 US hospitals over a 7-year period from March 1995 through September 2002 (60 cases per 10,000 hospital admissions). Eighty-seven percent of BSIs were monomicrobial. Gram-positive organisms caused 65% of these BSIs, gram-negative organisms caused 25%, and fungi caused 9.5%. The crude mortality rate was 27%. The most-common organisms causing BSIs were coagulase-negative staphylococci (CoNS) (31% of isolates), Staphylococcus aureus (20%), enterococci (9%), and Candida species (9%). The mean interval between admission and infection was 13 days for infection with Escherichia coli, 16 days for S. aureus, 22 days for Candida species and Klebsiella species, 23 days for enterococci, and 26 days for Acinetobacter species. CoNS, Pseudomonas species, Enterobacter species, Serratia species, and Acinetobacter species were more likely to cause infections in patients in intensive care units (P<.001). In neutropenic patients, infections with Candida species, enterococci, and viridans group streptococci were significantly more common. The proportion of S. aureus isolates with methicillin resistance increased from 22% in 1995 to 57% in 2001 (P<.001, trend analysis). Vancomycin resistance was seen in 2% of Enterococcus faecalis isolates and in 60% of Enterococcus faecium isolates. CONCLUSION: In this study, one of the largest multicenter studies performed to date, we found that the proportion of nosocomial BSIs due to antibiotic-resistant organisms is increasing in US hospitals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the United States and elsewhere, Candida species are a leading cause of health care–associated bloodstream infections (3–5).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [4]
In the citing paper
“The incidence of nosocomial candidiasis has increased over the past few decades [28,29,30,31,32].”
From Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision (2017) · cites this paper as [32]
In the citing paper
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
From Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision (2017) · cites this paper as [32]
In the citing paper
“Data from a US surveillance study found that over a 7year period Candida spp.accounted for 4.6 bloodstream infections per 10,000 admissions and 9% of all bloodstream infections [1], whereas the incidence may vary between centers.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [1]
In the citing paper
“Among documented invasive fungal infections, candidemia and invasive candidiasis are encountered with increasing incidence in nosocomial settings [1].”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [1]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Ibrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 1×
“[30] showed that mortality rates doubled, from 30% to 60%, when inappropriate empirical antibiotic therapy was given to ICU patients with BSIs.”
BackgroundNosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387 · cited 3×
“In addition, antibiotic resistance rates have been rising during the past 2 decades for all predominant organisms, including Staphylococcus aureus [14, 16, 17], coagulase-negative staphylococci [18, 19], enterococci [20], and gram-negative pathogens [15, 21, 22].”
BackgroundMethodSelf-citationDiekema, D. J., Pfaller, M. A., Schmitz, F. J., Smayevsky, J., Bell, J., Jones, R. N., Beach, M., & SENTRY Participants Group (2001) · Clinical Infectious Diseases · doi:10.1086/320184 · Cited by 1,362 · cited 1×
“In addition, antibiotic resistance rates have been rising during the past 2 decades for all predominant organisms, including Staphylococcus aureus [14, 16, 17], coagulase-negative staphylococci [18, 19], enterococci [20], and gram-negative pathogens [15, 21, 22].”
BackgroundWeinstein, M. P., Towns, M. L., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Barth Reller, L. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,228 · cited 1×
“Recent studies have shown that the proportion of contaminants is lower if 2 or more positive blood culture results (of samples drawn within a few hours of each other) were required for inclusion [9, 32, 33].”
BackgroundPittet, D. (1994) · JAMA · doi:10.1001/jama.1994.03510440058033 · Cited by 926
Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A., Gaynes, R. P., & Hospitals, T. N. N. I. S. S. (2002) · Clinical Infectious Diseases · doi:10.1086/342300 · Cited by 660
Kreger, B. E., Craven, D. E., Carling, P. C., & McCabe, W. R. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90101-1 · Cited by 595 · cited 1×
“The crude rate mortality ranged from 12% in total hospital populations to 80% in ICU patients [6–10].”
BackgroundEmergence of Vancomycin Resistance in Coagulase-Negative Staphylococci
Schwalbe, R. S., Stapleton, J. T., & Gilligan, P. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161507 · Cited by 584 · cited 1×
“In addition, antibiotic resistance rates have been rising during the past 2 decades for all predominant organisms, including Staphylococcus aureus [14, 16, 17], coagulase-negative staphylococci [18, 19], enterococci [20], and gram-negative pathogens [15, 21, 22].”
BackgroundFridkin, S. K., Steward, C. D., Edwards, J. R., Pryor, E. R., McGowan, Jr., Archibald, L. K., Gaynes, R. P., & Tenover, F. C. (1999) · Clinical Infectious Diseases · doi:10.1086/520193 · Cited by 486
Research works printed but not linked: 1
- 1996, 77, 791, 10.1002/(SICI)1097-0142(19960215)77:4<791::AID-CNCR27>3.0.CO;2-V · DOI · Paper page
Cited by
Items 301–400 of 1,033
Risk factors for invasive fungal disease in critically ill adult patients: a systematic review
Muskett, H., Shahin, J., Eyres, G., Harvey, S., Rowan, K., & Harrison, D. (2011) · Critical Care · doi:10.1186/cc10574 · Cited by 150
“The majority of IFD in the critical care setting is due to Candida species [2,3].”
BackgroundRivera, A. M., & Boucher, H. W. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0514 · Cited by 178
Salgado-Pabón, W., Breshears, L., Spaulding, A. R., Merriman, J. A., Stach, C. S., Horswill, A. R., Peterson, M. L., & Schlievert, P. M. (2013) · mBio · doi:10.1128/mbio.00494-13 · Cited by 153
Bloodstream infections: mechanisms of pathogenesis and opportunities for intervention
Holmes, C. L., Albin, O. R., Mobley, H. L. T., & Bachman, M. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01105-2 · Cited by 183
“About half of hospital-associated BSIs occur in intensive care units, with other wards, including internal medicine, surgery and paediatrics, also commonly reporting these infections 3,6 .”
Vancomycin-resistant enterococci (VRE): transmission and control
Tacconelli, E., & Cataldo, M. A. A. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.08.026 · Cited by 190
“aecium isolates were vancomycin-resistant [3].”
BackgroundHata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149
“There is still, however, a high rate of morbidity and mortality associated with invasive fungal infections (3, 17, 20, 45), because the currently available antifungal drugs, such as polyenes, azoles, and echinocandins, are limited in terms of their antifungal spectrum, side effects, and mode of action (7).”
BackgroundCandida biofilm: a well-designed protected environment
Mukherjee, P. K., Zhou, G., Munyon, R., & Ghannoum, M. A. (2005) · Medical Mycology · doi:10.1080/13693780500107554 · Cited by 148
Liu, S., Hou, Y., Chen, X., Gao, Y., Li, H., & Sun, S. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.12.009 · Cited by 164
Impact of Therapeutic Strategies on the Prognosis of Candidemia in the ICU*
Puig-Asensio, M., Pemán, J., Zaragoza, R., Garnacho-Montero, J., Martín-Mazuelos, E., Cuenca-Estrella, M., & Almirante, B. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000221 · Cited by 147
Dierkes, C., Ehrenstein, B., Siebig, S., Linde, H.-J., Reischl, U., & Salzberger, B. (2009) · BMC Infectious Diseases · doi:10.1186/1471-2334-9-126 · Cited by 147
“Invasive fungal infections have an especially high mortality [4,12,13].”
Mucosal Immunity and Candida albicans Infection
Moyes, D. L., & Naglik, J. R. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/346307 · Cited by 138
“Here, we review current knowledge of the interactions between C. albicans and epithelial surfaces and how this may shape our understanding of microbial-mucosal interactions.”
BackgroundIncidence and bacteriology of burn infections at a military burn center
Keen, E. F., ROBINSON, B. J., Hospenthal, D. R., Aldous, W. K., Wolf, S. E., Chung, K. K., & Murray, C. K. (2010) · Burns · doi:10.1016/j.burns.2009.10.012 · Cited by 151
“baumannii, day 26 and are associated with crude mortality [23].”
BackgroundInfluentialSpellberg, B., Ibrahim, A. S., Yeaman, M. R., Lin, L., Fu, Y., Avanesian, V., Bayer, A. S., Filler, S. G., Lipke, P., Otoo, H., et al. (2008) · Infection and Immunity · doi:10.1128/iai.00700-08 · Cited by 146
“Thus, the rAls3p-N vaccine mediated protection in mice against a fungal pathogen and a bacterial pathogen that jointly cause at least 200,000 clinical bloodstream infections, resulting in billions of dollars of health care expenditures and 40,000 to 50,000 deaths per year in the United States alone (5, 6, 10, 12, 19,…”
BackgroundPalraj, R., Baddour, L. M., Hess, E. P., Steckelberg, J. M., Wilson, W. R., Lahr, B. D., & Sohail, M. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ235 · Cited by 156
“Staphylococcus aureus is a highly virulent pathogen that has become a leading cause of bacteremia in both community and healthcare settings, accounting for 20% of all healthcare-associated bacteremias [1,2].”
BackgroundGazendam, R. P., van de Geer, A., Roos, D., van den Berg, T. K., & Kuijpers, T. W. (2016) · Immunological Reviews · doi:10.1111/imr.12454 · Cited by 144
Ortega, M., Marco, F., Soriano, À., Almela, M., Martínez, J. A., López, J. D. S., Pitart, C., & Mensa, J. (2011) · Journal of Hospital Infection · doi:10.1016/j.jhin.2010.09.026 · Cited by 175
Emerging Technologies for Rapid Identification of Bloodstream Pathogens
Kothari, A., Morgan, M., & Haake, D. A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu292 · Cited by 145
“Staphylococcus aureus is a cause of 20% of nosocomial BSI in the US [13].”
BackgroundRisk factors of catheter- associated bloodstream infection: Systematic review and meta-analysis
Cabrero, E. L., Terradas, R., Cuñado, A. C., Sardelli, D. G., López, C. H., Giró‐Formatger, D., Lacueva‐Pérez, L., Esquinas, C., & Tortosa, A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282290 · Cited by 176
“Moreover, the high prevalence of this complication has led to it becoming one of the major causes of morbidity and mortality in hospitalized patients [5, 11].”
BackgroundLefort, A., Panhard, X., Clermont, O., Woerther, P., Branger, C., Mentré, F., Fantin, B., Wolff, M., & Denamur, É. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01902-10 · Cited by 152
Positive Fungal Cultures in Burn Patients: A Multicenter Review
Ballard, J., Edelman, L., Saffle, J., Sheridan, R., Kagan, R., Bracco, D., Cancio, L., Cairns, B., Baker, R., Fillari, P., et al. (2008) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e31815f6ecb · Cited by 143
“Candida albicans is now the fourth most common organism found in blood cultures in intensive care unit (ICU) patients.(4,5) As efforts to control these infections have intensified, isolates of resistant strains and of previously rare fungal species, including non-albicans Candida, and molds including Aspergillus have…”
BackgroundKallikrein Cleaves C3 and Activates Complement
Irmscher, S., Döring, N., Halder, L. D., Jo, E. A. H., Kopka, I., Dunker, C., Jacobsen, I. D., Luo, S., Slevogt, H., Lorkowski, S., et al. (2018) · Journal of Innate Immunity · doi:10.1159/000484257 · Cited by 141
Cornely, O. A., Gachot, B., Akan, H., Bassetti, M., Uzun, O., Kibbler, C., Marchetti, O., de Burghgraeve, P., Ramadan, S., Pylkkanen, L., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ293 · Cited by 142
Modulation of Morphogenesis in Candida albicans by Various Small Molecules
Shareck, J., & Belhumeur, P. (2011) · Eukaryotic Cell · doi:10.1128/ec.05030-11 · Cited by 142
“albicans now ranks as the fourth leading cause of nosocomial infections and is the most common fungal species causing bloodstream infections, with associated mortality rates of 38 to 49% (62, 90, 111, 146).”
BackgroundStaphylococcus aureusbacteraemia and endocarditis – epidemiology and outcome: a review
Ásgeirsson, H., Thalme, A., & Weiland, O. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1392039 · Cited by 163
Toxin–antitoxin systems are ubiquitous and plasmid-encoded in vancomycin-resistant enterococci
Moritz, E. M., & Hergenrother, P. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601168104 · Cited by 141
Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia
Plantinga, T. S., Johnson, M. D., Scott, W. K., van de Vosse, E., Velez Edwards, D. R., Smith, P. B., Alexander, B. D., Yang, J. C., Kremer, D., Laird, G. M., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir867 · Cited by 141
“species) is the fourth most common nosocomial infection in immunocompromised patients and the systemic infections with the highest mortality rate, reaching 30%– 40% in intensive care unit (ICU) patients [1, 2].”
BackgroundNucci, M., & Colombo, A. L. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.11.009 · Cited by 164
“96 cases per 1000 admissions (Pittet and Wenzel, 1995; Tortorano et al., 2004; Wisplinghoff et al., 2004).”
Baygar, T., Saraç, N., Uğur, A., & Karaca, İ. R. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.12.034 · Cited by 151
Marinach, C., Alanio, A., Palous, M., Kwasek, S., Fekkar, A., Brossas, J., Brun, S., Snounou, G., Hennequin, C., Sanglard, D., et al. (2009) · PROTEOMICS · doi:10.1002/pmic.200900152 · Cited by 159
“albicans, the most important hospital-acquired fungal blood infections [8].”
BackgroundVitamin D and Infectious Diseases: Simple Bystander or Contributing Factor?
Gois, P. H. F., Ferreira, D., Olenski, S., & Seguro, A. C. (2017) · Nutrients · doi:10.3390/nu9070651 · Cited by 148
“Therefore, in the last decade, antifungal resistance became a matter of great public health concern [97,104].”
BackgroundChallenges and strategies in drug delivery systems for treatment of pulmonary infections
Ho, D., Nichols, B. L. B., Edgar, K. J., Murgia, X., Loretz, B., & Lehr, C. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.09.002 · Cited by 151
Klingspor, L., Tortorano, A. M., Peman, J., Willinger, B., Hamal, P., Sendid, B., Velegraki, A., Kibbler, C., Meis, J. F., Sabino, R., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.08.011 · Cited by 137
“A nationwide US surveillance study demonstrated that the crude mortality rate of IC was 47% for patients in intensive care units (ICUs) and 29% for patients in a hospital ward [4].”
BackgroundEpidemiology of fungal infections in China
Chen, M., Xu, Y., Hong, N., Yang, Y., Lei, W., Du, L., Zhao, J., Lei, X., Xiong, L., Cai, L., et al. (2018) · Frontiers of Medicine · doi:10.1007/s11684-017-0601-0 · Cited by 137
Nylon-3 Polymers with Selective Antifungal Activity
Liu, R., Chen, X., Hayouka, Z., Chakraborty, S., Falk, S. P., Weisblum, B., Masters, K. S. B., & Gellman, S. H. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4006404 · Cited by 144
Ruhnke, M., Rickerts, V., Cornely, O. A., Buchheidt, D., Glöckner, A., Heinz, W., Höhl, R., Horré, R., Karthaus, M., Kujath, P., et al. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02040.x · Cited by 149
Britt, N. S., Potter, E. M., Patel, N., & Steed, M. E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ444 · Cited by 142
“As many as 28% of all enterococcal bloodstream isolates are now resistant to vancomycin, including a majority of Enterococcus faecium strains [1].”
BackgroundNicasio, A. M., Kuti, J. L., & Nicolau, D. P. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.2.235 · Cited by 155
Magill, S. S., Shields, C., Sears, C. L., Choti, M., & Merz, W. G. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.2.529-535.2006 · Cited by 139
“account for 9% of nosocomial bloodstream infections (BSIs), making Candida the fourth most common cause of nosocomial BSIs in the United States (23).”
BackgroundInfluentialFungal persister cells: The basis for recalcitrant infections?
Wuyts, J., Van Dijck, P., & Holtappels, M. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007301 · Cited by 136
Zimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136
“FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance Alicia J. Zimbeck,1 Naureen Iqbal,1 Angela M. Ahlquist,1,2 Monica M. Farley,3,4 Lee H. Harrison,5 Tom Chiller,1 and Shawn R. Lockhart1* Mycotic Disease Branch, Centers for Disease Control and Prev…”
BackgroundDas, I., Nightingale, P., Patel, M., & Jumaa, P. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.06.006 · Cited by 137
Systemic antifungal therapy in critically ill patients without invasive fungal infection*
Azoulay, E., Dupont, H., Tabah, A., Lortholary, O., Stahl, J.-P., Francais, A., Martin, C., Guidet, B., & Timsit, J.-F. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e318236f297 · Cited by 138
Navarro-Arias, M. J., Hernández-Chávez, M. J., Garcia-Carnero, L. C., Amezcua-Hernández, D. G., Lozoya-Pérez, N. E., Estrada-Mata, E., Martínez-Duncker, I., Franco, B., & Mora-Montes, H. M. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s197531 · Cited by 134
“krusei the mortality rate is higher (20%–67%), likely related to their poor response to standard antifungal therapies.(6,8,9,11) Candida auris is an emergent fungal species, firstly identified in 2009 as an etiological agent of candidiasis, and has a natural resistance to several of the antifungal drugs used to treat…”
BackgroundAntifungal serum concentration monitoring: an update
Goodwin, M. L., & Drew, R. H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm389 · Cited by 143
Inflammatory Monocytes Mediate Early and Organ-Specific Innate Defense During Systemic Candidiasis
Ngo, L. Y., Kasahara, S., Kumasaka, D. K., Knoblaugh, S. E., Jhingran, A., & Hohl, T. M. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit413 · Cited by 137
López, J. L. G., Vilela, A. A., del Palacio, E. F., Corral, J., Martí, C. B., & Portal, P. H. (2013) · Journal of Hospital Infection · doi:10.1016/j.jhin.2013.10.008 · Cited by 167
“on hospital wards).(30,31) However, in light of the current economic crisis, the main finding of this study was the identification of indwell times for safe and effective routine replacement of PIVCs, thus saving on consumption and costs.”
BackgroundPosaconazole: An extended-spectrum triazole antifungal agent
SCHILLER, D., & Fung, H. B. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.015 · Cited by 153
Immune Response of Galleria mellonella against Human Fungal Pathogens
Trevijano-Contador, N., & Zaragoza, O. (2018) · Journal of Fungi · doi:10.3390/jof5010003 · Cited by 134
Sherry, L., Rajendran, R., Lappin, D. F., Borghi, E., Perdoni, F., Falleni, M., Tosi, D., Smith, K., Williams, C., Jones, B., et al. (2014) · BMC Microbiology · doi:10.1186/1471-2180-14-182 · Cited by 134
“Background Bloodstream infections (BSI) caused by Candida species remain a frequent cause of morbidity and mortality, particularly within the immunocompromised population [1,2].”
BackgroundInfluentialKaasch, A. J., Fowler, V. G., Rieg, S., Peyerl-Hoffmann, G., Birkholz, H., Hellmich, M., Kern, W. V., & Seifert, H. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir320 · Cited by 134
Self-citationLiu, J.-Y., & Dickter, J. K. (2020) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2020.06.001 · Cited by 166
Klevens, R. M., Edwards, J. R., Gaynes, R. P., & System, N. N. I. S. (2008) · Clinical Infectious Diseases · doi:10.1086/591698 · Cited by 136
Florescu, I., Beuran, M., Dimov, R., Razbadauskas, A., Bochan, M. R., Fichev, G., Dukart, G., Babinchak, T., Cooper, C. A., Ellis‐Grosse, E. J., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn250 · Cited by 134
“Multidrug-resistant Gram-positive pathogens such as MRSA and VRE are an increasing cause of nosocomial infections such as cSSSI, bacteraemia, cIAI and pneumonia.(5,10,24) – 26 Inadequate antibiotic management of these infections is often associated with treatment failure, increasing mortality and higher costs.”
BackgroundWalraven, C. J., & Lee, S. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01351-12 · Cited by 132
“Candida species are associated with the highest overall crude mortality of all nosocomial bloodstream infections, comparable to that of Pseudomonas and exceeding that of Staphylococcus aureus infections (10).”
BackgroundRodríguez‐Baño, J., López-Prieto, M. D., Portillo, M. M., Retamar, P., Natera, C., Nuño, E., Herrero, M., del Arco, A., Muñoz, Á., Téllez, F., et al. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03089.x · Cited by 132
(1,3)- -D-Glucan as a Prognostic Marker of Treatment Response in Invasive Candidiasis
Jaijakul, S., Vazquez, J. A., Swanson, R. N., & Ostrosky-Zeichner, L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis456 · Cited by 134
“The incidence of invasive candidiasis in the United States has been increasing over the past 2 decades [1].”
BackgroundInfluentialA review of Candida species causing blood stream infection
Giri, S., & Kindo, A. (2012) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.99484 · Cited by 127
Buchan, B. W., Ginocchio, C. C., Manii, R., Cavagnolo, R. Z., Pancholi, P., Swyers, L., Thomson, R. B., Anderson, C. J., Kaul, K. L., & Ledeboer, N. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001478 · Cited by 131
“[5,6].”
Diagnosis of invasive candidiasis in the ICU
Eggimann, P., Bille, J., & Marchetti, O. (2011) · Annals of Intensive Care · doi:10.1186/2110-5820-1-37 · Cited by 131
T cells from patients with Candida sepsis display a suppressive immunophenotype
Spec, A., Shindo, Y., Burnham, C.-A. D., Wilson, S., Ablordeppey, E. A., Beiter, E. R., Chang, K., Drewry, A. M., & Hotchkiss, R. S. (2016) · Critical Care · doi:10.1186/s13054-016-1182-z · Cited by 128
“Conclusions The incidence of Candida bloodstream infection is increasing and Candida is currently one of the most common nosocomial bloodstream infections in many intensive care units (ICUs) [1, 2, 4, 5, 20, 21].”
BackgroundResultInfluentialThe risk and clinical outcome of candidemia depending on underlying malignancy
The French Mycoses Study Group, Lortholary, O., Renaudat, C., Sitbon, K., Desnos-Ollivier, M., Bretagne, S., & Dromer, F. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4743-y · Cited by 134
Marra, A. R., Edmond, M. B., Forbes, B. A., Wenzel, R. P., & Bearman, G. M. L. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.4.1342-1346.2006 · Cited by 130
“Staphylococcus aureus is a highly common cause of BSIs (27).”
BackgroundSelf-citationChandra, J., McCormick, T. S., Imamura, Y., Mukherjee, P. K., & Ghannoum, M. A. (2007) · Infection and Immunity · doi:10.1128/iai.01841-06 · Cited by 130
“Candida species 3 have emerged as the fourth most common cause of nosocomial bloodstream infections (50), 4 with a significantly high attributable mortality (49%-71%) (14, 15).”
BackgroundEpidemiology of hospitalizations associated with invasive candidiasis, United States, 2002-20121
Strollo, S., Lionakis, M. S., Adjemian, J., Steiner, C. A., & Prevots, D. R. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2301.161198 · Cited by 129
Shiadeh, S. M. J., Pormohammad, A., Hashemi, A., & Lak, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s206084 · Cited by 158
Quorum sensing and Candida albicans
Kruppa, M. (2009) · Mycoses · doi:10.1111/j.1439-0507.2008.01626.x · Cited by 130
Molecular Mechanisms of Drug Resistance in Clinical Candida Species Isolated from Tunisian Hospitals
Eddouzi, J., Parker, J. E., Vale-Silva, L. A., Coste, A., Ischer, F., Kelly, S., Manai, M., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-13 · Cited by 128
“has been ranked as the fourth etiological agent causing bloodstream infections (4).”
BackgroundEnterococci as Indicators of Environmental Fecal Contamination
Boehm, A. B. B., & Sassoubre, L. M. (2014) · Cited by 128
Hsu, M.-S., Liao, C., Huang, Y., Liu, C., Yang, C., Kao, K., & Hsueh, P. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1223-0 · Cited by 128
“the timing of Acinetobacter bacteremia acquisition in a prospective US nationwide surveillance of nosocomial bloodstream infections [23].”
BackgroundDhand, A., & Sakoulas, G. (2012) · F1000 Medicine Reports · doi:10.3410/m4-4 · Cited by 141
“aureus isolates recovered in US intensive care units [1].”
Emergence of antimicrobial resistance among Acinetobacter species: a global threat
Clark, N. M., Zhanel, G. G., & Lynch, J. P. (2016) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000337 · Cited by 134
Pantosti, A., & Venditti, M. (2009) · European Respiratory Journal · doi:10.1183/09031936.00007709 · Cited by 164
Candida and invasive candidiasis: back to basics
Lim, C. S. Y., Rosli, R., Seow, H. F., & Chong, P. P. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1273-3 · Cited by 170
“The fourth most common cause of nosocomial (hospitalacquired) BSIs in the USA is Candida spp., accounting for 8–10% of all nosocomial BSIs [ 13 ], resulting in high personal and government treatment costs [14].”
BackgroundEffect of antifungal therapy timing on mortality in cancer patients with candidemia
Taur, Y., Cohen, N., Dubnow, S., Paskovaty, A., & Seo, S. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00945-09 · Cited by 127
“Candidemia has been reported to be the fourth most common hospital-associated bloodstream infection in the United States (48).”
BackgroundPhotodynamic inactivation for controlling Candida albicans infections
Gonzales, F. P., & Maisch, T. (2011) · Fungal Biology · doi:10.1016/j.funbio.2011.10.001 · Cited by 142
The Antifungal Activity of Naphthoquinones: An Integrative Review
Futuro, D. O., Ferreira, P. G., Nicoletti, C. D., Borba-Santos, L. P., da Silva, F. D. C., Rozental, S., & Ferreira, V. F. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170815 · Cited by 142
Alexander, B. D., Byrne, T. C., Smith, K. L., Hanson, K. E., Anstrom, K. J., Perfect, J. R., & Reller, L. B. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01840-06 · Cited by 129
“In order to ensure general applicability of the study results, our selection of isolates for testing included a spectrum of Candida species typically isolated in a clinical microbiology laboratory and mirrored national and international epidemiological data (35).”
ResultMatsumura, Y., Yamamoto, M., Nagao, M., Komori, T., Fujita, N., Hayashi, A., Shimizu, T., Watanabe, H., Doi, S., Tanaka, M., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-15 · Cited by 129
“Bacteremia caused by Escherichia coli is a common and significant problem in both community and health care settings (1).”
BackgroundThioredoxin Regulates Multiple Hydrogen Peroxide-Induced Signaling Pathways in Candida albicans
da Silva Dantas, A., Patterson, M. J., Smith, D. A., MacCallum, D. M., Erwig, L. P., Morgan, B. A., & Quinn, J. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00313-10 · Cited by 128
“Significantly, despite advances in antifungal therapy (40), Candida species remain the fourth leading cause of hospital-acquired bloodstream infections in the United States, with a mortality rate of 30% (59).”
BackgroundCandida tropicalis in human disease
Ann Chai, L. Y., Denning, D. W., & Warn, P. (2010) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2010.489506 · Cited by 122
“…(BSI) caused by Candida species has risen 5–10 fold to become the fourth leading cause of nosocomial bloodstream infections (BSI) in developed countries (Wisplinghoff et al. 2004; Pfaller et al. 2001) with incidence rates of up to 20 per 10,000 hospital discharges in the US (Pfaller et al. 2007a).”
BackgroundNguyen, M. H., Clancy, C. J., Pasculle, A. W., Pappas, P. G., Alangaden, G. J., Pankey, G. A., Schmitt, B. H., Rasool, A., Weinstein, M. P., Widen, R. E., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-2772 · Cited by 130
Cerca, N., Jefferson, K. K., Maira-Litrán, T., Pier, D. B., Kelly-Quintos, C., Goldmann, D. A., Azeredo, J., & Pier, G. B. (2007) · Infection and Immunity · doi:10.1128/iai.00078-07 · Cited by 126
“Staphylococcus aureus and coagulase-negative staphylococci are the most frequent causes of nosocomial bloodstream infections (43).”
BackgroundAntimicrobial Resistance: It's Not Just for Hospitals
Bancroft, E. A. (2007) · JAMA · doi:10.1001/jama.298.15.1803 · Cited by 141
Pierce, C. G., Chaturvedi, A. K., Lazzell, A. L., Powell, A. T., Saville, S. P., McHardy, S. F., & Lopez-Ribot, J. L. (2015) · npj Biofilms and Microbiomes · doi:10.1038/npjbiofilms.2015.12 · Cited by 124
Grillon, A., Schramm, F., Kleinberg, M., & Jehl, F. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156690 · Cited by 124
“aeruginosa, in particular, is well recognized opportunist pathogen in immunocompromised patients [3], with a mortality rate as high as 50% [4].”
BackgroundAlves, M. J., Ferreira, I. C. F. R., Martins, A., & Pintado, M. (2012) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2012.05347.x · Cited by 126
“…multiresistance problem, the nosocomial infections (healthcare-associated infections) are associated with high mortality and also with the increase in the internment period and related costs (Orsi et al. 2002; Masterton et al. 2003; Wisplinghoff et al. 2004; Sǔljagić et al. 2005; Cosgrove 2006).”
BackgroundEfficacy of Ethanol against Candida albicans and Staphylococcus aureus Polymicrobial Biofilms
Peters, B. M., Ward, R. M., Rane, H. S., Lee, S. A., & Noverr, M. C. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01599-12 · Cited by 145
Antifungal stewardship considerations for adults and pediatrics
Hamdy, R. F., Zaoutis, T. E., & Seo, S. K. (2016) · Virulence · doi:10.1080/21505594.2016.1226721 · Cited by 132
“Although invasive mucormycosis should be considered in the differential diagnosis for patients with suspected IFI, diagnosis still relies on histopathologic and culture confirmation; studies looking into the feasibility of using polymerase chain reaction (PCR) on tissue specimens and serum remain investigational to da…”
BackgroundTien, B. Y. Q., Goh, H. M. S., Chong, K. K. L., Bhaduri-Tagore, S., Holec, S., Dress, R. J., Ginhoux, F., Ingersoll, M. A., Williams, R. B. H., & Kline, K. A. (2017) · Infection and Immunity · doi:10.1128/iai.00378-17 · Cited by 132
Immunity to Commensal Fungi: Detente and Disease
Wheeler, M. L., Limon, J. J., & Underhill, D. M. (2017) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100342 · Cited by 130
“After some common bacteria, Candida is the fourth most frequent cause of hospital-acquired blood infections (66).”
The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications
Wagner, C., Graninger, W., Presterl, E., & Joukhadar, C. (2006) · Pharmacology · doi:10.1159/000096348 · Cited by 125
“Increasing infections with opportunistic fungal organisms are the result of improved survival of patients in the intensive care unit, increasing catheterization and more aggressive immunosuppression. Candidiasis and aspergillosis are the most frequent nosocomial and community-acquired fungal infections [”
BackgroundKauffman, C. A. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200510-110jh · Cited by 114
Teicoplanin versus vancomycin for proven or suspected infection
Cavalcanti, A. B., Gonçalves, A., Almeida, C. S., Bugano, D. D. G., & Silva, E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007022.pub2 · Cited by 140
Al‐Hasan, M. N., Lahr, B. D., Eckel-Passow, J. E., & Baddour, L. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp162 · Cited by 125
Ostrosky-Zeichner, L., Pappas, P. G., Shoham, S., Reboli, A., Barron, M. A., Sims, C., Wood, C., & Sobel, J. D. (2011) · Mycoses · doi:10.1111/j.1439-0507.2009.01756.x · Cited by 121
Timing of Specimen Collection for Blood Cultures from Febrile Patients with Bacteremia
Riedel, S. F., Bourbeau, P. P., Swartz, B., Brecher, S., Carroll, K. C., Stamper, P. D., Dunne, W. M., McCardle, T. W., Walk, N., Fiebelkorn, K. R., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02033-07 · Cited by 122
“Bloodstream infections (BSIs) occur more than 200,000 times annually in the United States, with associated mortality rates of 35 to 60% (20, 33, 34).”
BackgroundHeilmann, C. J., Sorgo, A. G., Mohammadi, S., Sosinska, G. J., de Koster, C. G., Brul, S., de Koning, L. J., & Klis, F. M. (2013) · Eukaryotic Cell · doi:10.1128/ec.00278-12 · Cited by 122
“It is one of the leading causes of fungal infections among immunocompromised patients, which are often fatal if not diagnosed in time (1, 2).”
BackgroundHanson, K. E., Pfeiffer, C. D., Lease, E. D., Balch, A. H., Zaas, A. K., Perfect, J. R., & Alexander, B. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042282 · Cited by 122
“glabrata, a species that is often fluconazole resistant, and other non-albicans Candida species [4,5,6].”
BackgroundDevelopment of a vaccine against Staphylococcus aureus
Spellberg, B. J., & Daum, R. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0293-5 · Cited by 134
“It is the most common cause of culture-confirmed skin and soft tissue infections (SSTIs) [1–4] and endocarditis [5], and is the second most common cause of bacteremia [6, 7].”
BackgroundRapid Detection of Bacteria from Blood with Surface-Enhanced Raman Spectroscopy
Boardman, A. K., Wong, W. S., Premasiri, W. R., Ziegler, L. D., Lee, J. C., Miljković, M. D., Klapperich, C. M., Sharon, A., & Sauer-Budge, A. F. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01273 · Cited by 128
Metadata
- Authors
- Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B.
- Affiliations
- University of Cologne (DE)
- Virginia Commonwealth University (US)
- Corresponding author
- Edmond, M. B.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-01
- Volume
- 39
- Issue
- 3
- Pages
- 309-317
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2171155970
- Cited by
- 4,496
- References
- 42
- Citations by year
- 2026: 78 · 2025: 138 · 2024: 137 · 2023: 171 · 2022: 209 · 2021: 187 · 2020: 229 · 2019: 252 · 2018: 215 · 2017: 238 · 2016: 255 · 2015: 271 · 2014: 291 · 2013: 257 · 2012: 241
- FWCI
- 105.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- nosocomial bloodstream infection, nosocomial infections, antibiotic resistance, methicillin-resistant Staphylococcus aureus, vancomycin resistance, Enterococcus faecium, Enterococcus faecalis, coagulase-negative staphylococci, candidiasis, intensive care unit, neutropenic patients, infectious disease epidemiology, temporal trends
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Candidiasis, Child, Child, Preschool, Cross Infection, Drug Resistance, Microbial, Female, Humans, Infant, Male, Middle Aged, Population Surveillance, Prospective Studies, Staphylococcal Infections, United States, Causality, Incidence, Fungemia, Bacteremia, Gram-Negative Bacterial Infections, Gram-Positive Bacterial Infections, Sepsis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.